Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Pamela S. Smith"'
1
X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231AG (A Retrospective Case-Control Study)
Autor: Beatriz Francesca Ramirez, Pamela S Smith, Fan Zhang, Deborah Wenkert, Valerie A. Wollberg, Gary S. Gottesman, Margaret Huskey, Fiona J. Cook, Steven Mumm, Michael P. Whyte
Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchReferences. 35(5)
X-linked hypophosphatemia (XLH), the most prevalent heritable renal phosphate (Pi) wasting disorder, is caused by deactivating mutations of PHEX. Consequently, circulating phosphatonin FGF23 becomes elevated and hypophosphatemia in affected children
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43b141bc1dc8f4dc33290850ae64c8b0
https://pubmed.ncbi.nlm.nih.gov/31910300
Zobrazit plný text záznamu
2
SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
Autor: Gary S. Gottesman, Ana Maria Arbelaez, William H. McAlister, Susan J. Bayliss, Michael P. Whyte, Marwan Shinawi, Pamela S Smith, Jeffrey L Sugarman
Publikováno v: Journal of the Endocrine Society
Background: Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaicism of a RAS family gene (ie. HRAS, NRAS, KRAS). CSHS features: 1) congenital epidermal, melanocytic, or sebaceous nevi, 2) elevated circulating FGF23 levels t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::993ffd1794f59cfef55b87d1f857d27c
https://doi.org/10.1210/js.2019-sat-lb085
Zobrazit plný text záznamu
3
Management of End-Stage Renal Disease in Children
Autor: Pamela S Smith
Publikováno v: Annals of Pharmacotherapy. 32:929-939
OBJECTIVE:To review the medical literature on management of end-stage renal disease (ESRD) and its complications in the pediatric patient.DATA SOURCES AND STUDY SELECTION:MEDLINE searches (1970–1997) of the English-language literature. Clinical tri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec665e5811aba6a45fd312ba32a0f81e
https://doi.org/10.1345/aph.17369
Zobrazit plný text záznamu
5
Surviving the prejudice of obesity
Autor: Pamela S. Smith
Publikováno v: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates. 30(3)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90075051ca391fb924c6e7e58faab5f3
https://pubmed.ncbi.nlm.nih.gov/17568265
Zobrazit plný text záznamu
7
Maximum a Posteriori (MAP) Estimates for Hyperspectral Image Enhancement
Autor: Pamela S. Smith, Andrew C. Lindgren, Russell C. Hardie, Gregory L. Wilson, Thomas M. Fitzgerald
In completing this Phase 2 SBIR, ATK Mission Research with help from the University of Dayton, has accomplished the intended goal of the SBIR program by developing a commercially marketable Hyperspectral Image Enhancement system. This system implemen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::620e35e7a93e666694836d2037672225
https://doi.org/10.21236/ada429581
Zobrazit plný text záznamu
8
A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes
Autor: Rami S. Komrokji, Pamela S Smith, Alan F. List, Jeffrey E. Lancet, Daohai Yu, Yuraima Rodriguez, William J. Fulp
Publikováno v: Blood. 118:1714-1714
Abstract 1714 BACKGOUND Erlotinib is an oral small molecule tyrosine kinase inhibitor that inhibits intracellular EGFR tyrosine kinase. Preclinical data suggest that erlotinib has in vivo and in vitro efficacy in MDS and AML (Boehrer et al., Blood, 2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4a65bc4da9592442fc221e799e652ed
https://doi.org/10.1182/blood.v118.21.1714.1714
Zobrazit plný text záznamu
9
Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study
Autor: Darcie Deaver, Enrique Santana, Rami S. Komrokji, Daohai Yu, Ling Zhang, Alan F. List, Jeffrey E. Lancet, Pamela S Smith, Sara Tinsley, Lulu Yan
Publikováno v: Blood. 116:1854-1854
Abstract 1854 Backgound: Erlotinib is an oral small molecule tyrosine kinase inhibitor that inhibits intracellular EGFR tyrosine kinase. Preclinical data suggest that erlotinib has in vivo and in vitro efficacy in MDS and AML (Boehrer et al., Blood,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ea759cb4618b29eff8bd4726a52a5dd
https://doi.org/10.1182/blood.v116.21.1854.1854
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje